Volker Heinemann mostly deals with Internal medicine, Oncology, Colorectal cancer, Cetuximab and KRAS. His Internal medicine research incorporates themes from Gastroenterology and Surgery. His Oncology research includes elements of Clinical trial, Irinotecan, Metastasis, Hazard ratio and Bevacizumab.
His Colorectal cancer research includes themes of Clinical endpoint, Randomized controlled trial and Progression-free survival. His Cetuximab research focuses on Targeted therapy and how it relates to Biomarker. His KRAS study which covers Bioinformatics that intersects with RAS Mutation, Treatment outcome and Folinic acid.
His primary areas of investigation include Internal medicine, Oncology, Colorectal cancer, Cetuximab and Bevacizumab. His work is dedicated to discovering how Internal medicine, Gastroenterology are connected with Pathology and other disciplines. His Oncology research is multidisciplinary, incorporating perspectives in KRAS, Irinotecan, Surgery and Oxaliplatin.
His study in Colorectal cancer is interdisciplinary in nature, drawing from both Cancer research, Progression-free survival, Proportional hazards model, Hazard ratio and Single-nucleotide polymorphism. He interconnects Cohort and First line in the investigation of issues within Bevacizumab. His Pancreatic cancer research integrates issues from Biomarker and Erlotinib.
His scientific interests lie mostly in Internal medicine, Oncology, Colorectal cancer, Cetuximab and Bevacizumab. Internal medicine is closely attributed to Gastroenterology in his study. In Oncology, he works on issues like FOLFOXIRI, which are connected to Wild type.
His work on KRAS as part of general Colorectal cancer study is frequently linked to In patient, bridging the gap between disciplines. Volker Heinemann combines subjects such as First line and Epidermal growth factor receptor with his study of Bevacizumab. In his research on the topic of Irinotecan, Fluorouracil is strongly related with Oxaliplatin.
Volker Heinemann focuses on Internal medicine, Oncology, Colorectal cancer, Bevacizumab and FOLFIRI. His Internal medicine study frequently draws parallels with other fields, such as Gastroenterology. His work deals with themes such as First line treatment, Cancer immunotherapy, Proportional hazards model, FOLFOXIRI and Panitumumab, which intersect with Oncology.
His Colorectal cancer research is multidisciplinary, incorporating elements of Fluorouracil, Progression-free survival, Cohort and Hazard ratio. His Bevacizumab research includes elements of Cetuximab, Randomized controlled trial and MEDLINE. His FOLFIRI study incorporates themes from Odds ratio and Targeted therapy.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial
Volker Heinemann;Ludwig Fischer von Weikersthal;Thomas Decker;Alexander Kiani.
Lancet Oncology (2014)
Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial.
Salah-Eddin Al-Batran;Nils Homann;Claudia Pauligk;Thorsten O Goetze.
The Lancet (2019)
Randomized Phase III Trial of Gemcitabine Plus Cisplatin Compared With Gemcitabine Alone in Advanced Pancreatic Cancer
Volker Heinemann;Detlef Quietzsch;Frank Gieseler;Michael Gonnermann.
Journal of Clinical Oncology (2006)
Prognostic and Predictive Relevance of Primary Tumor Location in Patients With RAS Wild-Type Metastatic Colorectal Cancer Retrospective Analyses of the CRYSTAL and FIRE-3 Trials
Sabine Tejpar;Sebastian Stintzing;Fortunato Ciardiello;Josep Tabernero.
JAMA Oncology (2017)
Meta-analysis of randomized trials: evaluation of benefit from gemcitabine-based combination chemotherapy applied in advanced pancreatic cancer
Volker Heinemann;Stefan Boeck;Axel Hinke;Roberto Labianca.
BMC Cancer (2008)
nab-Paclitaxel Plus Gemcitabine for Metastatic Pancreatic Cancer: Long-Term Survival From a Phase III Trial
David Goldstein;Robert Hassan El-Maraghi;Pascal Hammel;Volker Heinemann.
Journal of the National Cancer Institute (2015)
The relevance of primary tumour location in patients with metastatic colorectal cancer: A meta-analysis of first-line clinical trials
Julian Walter Holch;Ingrid Ricard;Sebastian Stintzing;Dominik Paul Modest.
European Journal of Cancer (2017)
Addressing the challenges of pancreatic cancer: future directions for improving outcomes
Manuel Hidalgo;Stefano Cascinu;Jörg Kleeff;Roberto Labianca.
Ratio of trastuzumab levels in serum and cerebrospinal fluid is altered in HER2-positive breast cancer patients with brain metastases and impairment of blood-brain barrier.
Hans-Joachim Stemmler;Manfred Schmitt;Amina Willems;Helga Bernhard.
Anti-Cancer Drugs (2007)
Prognosis of patients with peritoneal metastatic colorectal cancer given systemic therapy: an analysis of individual patient data from prospective randomised trials from the Analysis and Research in Cancers of the Digestive System (ARCAD) database
Jan Franko;Qian Shi;Jeffrey P Meyers;Timothy S Maughan.
Lancet Oncology (2016)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: